A Prospective Phase I Clinical Trial of Carbon Ion Radiation Therapy for Locally Advanced, Unresectable Pancreatic Cancer
A Prospective Phase I Clinical Trial of Carbon Ion Radiation Therapy for Locally Advanced, Unresectable Pancreatic Cancer
This is a phase I trial to determine the maximum tolerated dose of carbon ion radiotherapy for the treatment of locally advanced, unresectable, pancreatic cancer.
Inclusion Criteria:
Exclusion Criteria:
Lack of pathologic confirmation of pancreatic malignancy prior to treatment initiation;
ECOG Performance Status >=2;
Poor liver, kidney and bone marrow function that do not meet the requirements for treatment;
Persistent grade ≥ 2 toxicity due to previous cancer treatment;
Patient has previously received abdominal radiation therapy or abdominal radioactive seed implantation;
Those wearing a cardiac pacemaker or another type of metal prosthetic implant whose normal functions may suffer interference from high energy radiation or that could affect the radiation target area;
Where it is not possible to achieve the predetermined safety dose limit with the dose equivalent limit of the organ at risk such as the liver or digestive tract, etc.;
If the doctor determines that the heavy proton or carbon ion dosage radiotherapy will not bring any benefit to the patient;
Patients suffering from another illness or other factors that could affect the proton or carbon ion therapy;
Pregnant (verified by serum or urine β-HCG test) or breastfeeding females;
Drug-abuse or alcohol dependency;
HIV positive, including those that have received antiretroviral therapy; replicative stage of chronic Hepatitis B virus; active stage of Hepatitis C; and active stage of syphilis;
HBV positive patients suffering from replicative stage of hepatitis virus, requiring antiretroviral therapy but cannot due to a concomitant disease;
Patients with a history of mental illness that may prevent their completion of treatment;
Patients with serious complications that could affect the course of treatment, including:
Patients with contraindications to receiving radiotherapy, such as a serious connective tissue disease (eg: scleroderma)
Patients that are unable to understand the objective of the treatment/cannot sign the informed consent form;
Patients that lack civil capacity to act or whose civil capacity to act is limited.